Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7405455 | 0.98 | ALDH1A1 (0.70) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL31669175 | 0.98 | ALDH1A1 (0.74) | ALDH1A1KDM4EPOLBATMKMT2A | |
| Cyclopentanamine SCHEMBL5925376 | 0.88 | KDM4E (0.59) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL2090077 | 0.84 | KDM4E (0.62) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL19288785 | 0.84 | KDM4E (1.00) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL10129617 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL11619127 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL15859936 | 0.83 | KDM4E (0.67) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL1779555 | 0.83 | KDM4E (0.67) | ALDH1A1KDM4EPOLBATMKMT2A | |
| SCHEMBL14318329 | 0.83 | ALDH1A1 (0.88) | ALDH1A1KDM4EPOLBATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-106470990-A | pyridazine compounds | 武田药品工业株式会社 | 2017-03-01 | — | — | CN | disclosed |
| EP-2615916-B1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-04 | — | — | EP | disclosed |
| US-6723724-B2 | PSYCHOLOGICAL DISORDERS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-20 | — | — | US | disclosed |
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | DRD4, DRD3, DRD2 | ALDH1A1 429/4885KDM4E 1677/4885POLB 3948/4885 |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | ALDH1A1 2942/4885KDM4E 345/4885POLB 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.